Skip to main content
Erschienen in: Breast Cancer 1/2009

01.01.2009 | Case Report

Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report

verfasst von: Takashi Shigekawa, Hideki Takeuchi, Misono Misumi, Kazuo Matsuura, Hiroshi Sano, Nobuko Fujiuchi, Katsuhiko Okubo, Akihiko Osaki, Kenjiro Aogi, Toshiaki Saeki

Erschienen in: Breast Cancer | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

We report a case of metastatic breast cancer with leptomeninges and multiple bone metastases that showed an excellent response to the combination of trastuzumab and capecitabine; therapeutic effect was evaluated by MRI at follow-up. A 44-year-old woman underwent modified radical mastectomy in February 1997. In April 2003, a tumor at the right basis cerebri and multiple bone metastases were noted, and in October 2003, she underwent enucleation of the tumor. Histopathologically, the tumor was consistent with a basal skull metastasis from breast cancer. In March 2004, the patient began to experience pain, weakness, and paresthesia of both legs. She was diagnosed, with leptomeningeal metastasis (LM) from breast cancer using MRI. In December 2005, the combination of trastuzumab and capecitabine administered as sixth-line treatment was very effective for LM. Although it is generally very difficult to diagnose LM and assess the therapeutic effect with MRI, in this case, it was possible. To our knowledge, there has been no report in the literature describing the combination of trastuzumab and capecitabine for LM from breast cancer. Although the mechanism underlying the efficacy of this combination is still unknown, the treatment would be worth trying because of its few side effects in extensively treated patients with LM from breast cancer. To confirm the antitumor efficacy of trastuzumab and capecitabine, however, further investigations are required.
Literatur
1.
Zurück zum Zitat Grossman SA. Advances in the treatment of central nervous system metastases: treatment of leptomeningeal metastasis. In: Perry M, editor. Education book. Alexandria: American Society of Clinical Oncology; 2001. p. 598–604. Grossman SA. Advances in the treatment of central nervous system metastases: treatment of leptomeningeal metastasis. In: Perry M, editor. Education book. Alexandria: American Society of Clinical Oncology; 2001. p. 598–604.
2.
Zurück zum Zitat Boogerd W, Dorresteijn LD, van Der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology. 2000;12:117–9. Boogerd W, Dorresteijn LD, van Der Sande JJ, de Gast GC, Bruning PF. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology. 2000;12:117–9.
3.
Zurück zum Zitat DeAngelis L, Rogers L, Foley KM. Leptomeningeal metastasis. In: Harris JR, editor. Disease of the breast. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 867–74. DeAngelis L, Rogers L, Foley KM. Leptomeningeal metastasis. In: Harris JR, editor. Disease of the breast. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 867–74.
4.
Zurück zum Zitat Rogers LR, Remer SE, Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro-oncology. 2004;6(1):63–4.PubMedCrossRef Rogers LR, Remer SE, Tejwani S. Durable response of breast cancer leptomeningeal metastasis to capecitabine monotherapy. Neuro-oncology. 2004;6(1):63–4.PubMedCrossRef
5.
Zurück zum Zitat Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer. 2006;7(2):164–6.PubMedCrossRef Tham YL, Hinckley L, Teh BS, Elledge R. Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report. Clin Breast Cancer. 2006;7(2):164–6.PubMedCrossRef
6.
Zurück zum Zitat Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol. 2000;27:21–5.PubMed Pegram MD, Lopez A, Konecny G, Slamon DJ. Trastuzumab and chemotherapeutics: drug interactions and synergies. Semin Oncol. 2000;27:21–5.PubMed
7.
Zurück zum Zitat Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. Inhibitory effects of combinations of HER-2/neuantibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18:2241–51.PubMedCrossRef Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D. Inhibitory effects of combinations of HER-2/neuantibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999;18:2241–51.PubMedCrossRef
8.
Zurück zum Zitat Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25(22):3246–50.PubMedCrossRef Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25(22):3246–50.PubMedCrossRef
9.
Zurück zum Zitat Harris M, Howell A, Chrissohou M, Swindell RI, Hudson M, Sellwood RA. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer. 1984;50:23–30.PubMed Harris M, Howell A, Chrissohou M, Swindell RI, Hudson M, Sellwood RA. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer. 1984;50:23–30.PubMed
10.
Zurück zum Zitat Lamovec J, Zidar A. Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med. 1991;115:507–10.PubMed Lamovec J, Zidar A. Association of leptomeningeal carcinomatosis in carcinoma of the breast with infiltrating lobular carcinoma. An autopsy study. Arch Pathol Lab Med. 1991;115:507–10.PubMed
11.
Zurück zum Zitat Smith DB, Howell A, Harris M, Bramwell VH, Sellwood RA. Carcinomatous meningitis associated with infiltrating lobular carcinoma of the breast. Eur J Surg Oncol. 1985;11:33–6.PubMed Smith DB, Howell A, Harris M, Bramwell VH, Sellwood RA. Carcinomatous meningitis associated with infiltrating lobular carcinoma of the breast. Eur J Surg Oncol. 1985;11:33–6.PubMed
12.
Zurück zum Zitat Jayson GC, Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol. 1996;7:773–86.PubMed Jayson GC, Howell A. Carcinomatous meningitis in solid tumours. Ann Oncol. 1996;7:773–86.PubMed
13.
Zurück zum Zitat Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist. 2003;8(5):398–410.PubMedCrossRef Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist. 2003;8(5):398–410.PubMedCrossRef
14.
Zurück zum Zitat Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394–402.PubMed Glantz MJ, Jaeckle KA, Chamberlain MC, Phuphanich S, Recht L, Swinnen LJ, Maria B, LaFollette S, Schumann GB, Cole BF, Howell SB. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin Cancer Res. 1999;5:3394–402.PubMed
15.
16.
Zurück zum Zitat Berg SL, Chamberlain MC. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep. 2003;5:29–40.PubMedCrossRef Berg SL, Chamberlain MC. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr Oncol Rep. 2003;5:29–40.PubMedCrossRef
17.
Zurück zum Zitat Blum JL, Dieras V, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759–68.PubMedCrossRef Blum JL, Dieras V, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T. Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759–68.PubMedCrossRef
18.
Zurück zum Zitat Seidman AD, O’Shaughnessy J, Misset JL. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist. 2002;7(suppl 6):20–8.PubMedCrossRef Seidman AD, O’Shaughnessy J, Misset JL. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist. 2002;7(suppl 6):20–8.PubMedCrossRef
19.
Zurück zum Zitat McEvoy GK, editor: Capecitabine. In: AHFS Drug Information. Bethesda: American Society of Health-System Pharmacists, Inc.; 2002. p. 916–921. McEvoy GK, editor: Capecitabine. In: AHFS Drug Information. Bethesda: American Society of Health-System Pharmacists, Inc.; 2002. p. 916–921.
20.
Zurück zum Zitat Heier MS, Heintz R, Fossa SD. Passage of 5′-dFUrd and its metabolites 5-FU and 5-FUH2 to CSF in a clinical phase 1 study. Acta Neurol Scand. 1986;74:240–4.PubMedCrossRef Heier MS, Heintz R, Fossa SD. Passage of 5′-dFUrd and its metabolites 5-FU and 5-FUH2 to CSF in a clinical phase 1 study. Acta Neurol Scand. 1986;74:240–4.PubMedCrossRef
21.
Zurück zum Zitat Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol. 2001;24:421–4.PubMedCrossRef Wang ML, Yung WK, Royce ME, Schomer DF, Theriault RL. Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancer. Am J Clin Oncol. 2001;24:421–4.PubMedCrossRef
22.
Zurück zum Zitat Giglio P, Tremont-Lukats IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncology. 2003;6:63–4. Giglio P, Tremont-Lukats IW, Groves MD. Response of neoplastic meningitis from solid tumors to oral capecitabine. J Neurooncology. 2003;6:63–4.
23.
Zurück zum Zitat Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J. 2003;5:833–4.PubMed Siegelmann-Danieli N, Stein M, Bar-Ziv J. Complete response of brain metastases originating in breast cancer to capecitabine therapy. Isr Med Assoc J. 2003;5:833–4.PubMed
24.
Zurück zum Zitat Hikino H, Yamada T, Johbara K, Obayashi N, Ozaki N. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast. 2006;15:97–9.PubMedCrossRef Hikino H, Yamada T, Johbara K, Obayashi N, Ozaki N. Potential role of chemo-radiation with oral capecitabine in a breast cancer patient with central nervous system relapse. Breast. 2006;15:97–9.PubMedCrossRef
25.
Zurück zum Zitat DeVita VT Jr, Hellman S, Rosenberg S. Cancer: principles and practice of oncology: chap. 51; Treatment of metastatic cancer: sect. 1; Metastatic brain cancer. 7th ed. Lippincott Williams & Wilkins: Philadelphia; 2005. p. 2323–6. DeVita VT Jr, Hellman S, Rosenberg S. Cancer: principles and practice of oncology: chap. 51; Treatment of metastatic cancer: sect. 1; Metastatic brain cancer. 7th ed. Lippincott Williams & Wilkins: Philadelphia; 2005. p. 2323–6.
Metadaten
Titel
Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report
verfasst von
Takashi Shigekawa
Hideki Takeuchi
Misono Misumi
Kazuo Matsuura
Hiroshi Sano
Nobuko Fujiuchi
Katsuhiko Okubo
Akihiko Osaki
Kenjiro Aogi
Toshiaki Saeki
Publikationsdatum
01.01.2009
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 1/2009
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-008-0056-x

Weitere Artikel der Ausgabe 1/2009

Breast Cancer 1/2009 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.